VJHemOnc is committed to improving our service to you

EHA 2020 | Proteasome inhibitors in myeloma treatment

VJHemOnc is committed to improving our service to you

Rakesh Popat

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, of the University College London Hospitals, London, UK, explores the use of proteasome inhibitors in multiple myeloma treatment as well as new approaches investigated in the ENDURANCE study (NCT01863550), comparing RVD and kRD. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter